摘要
Survivin是迄今为止发现的与肿瘤最相关的特异性蛋白,其在几乎所有人类肿瘤中的表达都是上调的。由于它在肿瘤恶性程度方面的可上调性和在肿瘤的凋亡、增殖、血管新生方面的不可或缺性,survivin被认为可以作为抗肿瘤治疗的新靶点。目前正在进行研究的针对survivin的抗肿瘤制剂包括反义寡核苷酸类、siRNA、核酶、免疫治疗和小分子等。针对这些制剂的一些临床I/II期临床试验正在进行中。Survivin蛋白拮抗剂有望与传统的抗肿瘤治疗药物联合使用,发挥更好的治疗效果。
Survivin is a cancer-specific pro- tein, and it upregulated in almost all human tumors. Because of its upregulation in malignancy and its key role in apoptosis, proliferation and angiogenesis, survivin is considered as a new target for anti-cancer therapies. Strategies under the research to target survivin include antisense oligonucleotides, siRNA, ribozymes, immuno- therapy and small molecular weight molecules.Several phase I/Ⅱ vivin are currently vivin antagonists therapies might effect. clinical trials targeting sur- ongoing. The usage of sur- combined with conventional achieve better therapeutic
出处
《中国临床药理学与治疗学》
CAS
CSCD
2014年第7期835-840,共6页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
皖南医学院中青年自然科学基金项目(WK2012F09)
